Dawah Pharmaceuticals is About to Launch

NEW YORK - June 29, 2021 - PRLog -- Dawah Pharmaceuticals has been very active with its suppliers and regulatory
partners, preparing its product roll-out to the industry.

Our first drug, a paralytic, currently has favorable pricing, leading to higher revenues
and volumes. We have been issued our NDC number and the label to be placed on the
packaging and bottles. The ANDA is currently under review along with ongoing FDA
discussions to ensure timely approval.

Our second drug, an antipsychotic, is undergoing preparation to produce stability
batches. This drug is going to come in two dosage forms. The purpose of the
stability batches is for FDA approval. Dawah is currently reconfirming unit dose
vial sizes to meet the market demand. Currently, there are increased shortages in
the US market, which we anticipated in our earlier feasibility study.

We continue to focus on capital requirements to secure the necessary funding to
accelerate the identified pipeline further. In addition, we are working with potential
partners and vendors to strengthen Dawah's footprint in the market. Institutional
investor meetings continue to be ongoing.

We are excited about the next coming months knowing we are near a significant
milestone. We appreciate our current investors as they believe in our vision and look
forward to new investors who can still join a company achieving all that it set out to
accomplish.

If you have any questions, please contact us at info@dawahpharma.com.

http://www.dawahpharma.com